Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company's popular blood cancer drug Revlimid plummeted due to generic…